The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to United States-based Usona Institute's psilocybin intended for the treatment of major depressive disorder (MDD), it was reported yesterday.
Breakthrough Therapy Designation establishes the FDA's organisational commitment to promoting an efficient development program for psilocybin in MDD.
The new status follows the recent introduction of Usona's Phase two clinical trial, PSIL201, which included around 80 participants at seven study sites around the US. Two of the seven study sites are presently hiring, with the others expected to be active by the first quarter of 2020.
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD